Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Cortex Pharmaceuticals Inc. (RSPI) had Normalized Pre-Tax Income of $-2.10M for the most recently reported fiscal year, ending 2022-12-31.
| Income Statement Financials | |
-- |
|
$-3.97M |
|
-- |
|
-- |
|
$1.58M |
|
$-1.58M |
|
$-0.52M |
|
$-2.10M |
|
|
Normalized Pre-Tax Income |
$-2.10M |
$-2.10M |
|
$-2.10M |
|
$-2.10M |
|
$-2.10M |
|
$-1.58M |
|
$-1.19M |
|
111.32M |
|
111.32M |
|
$-0.04 |
|
$-0.04 |
|
| Balance Sheet Financials | |
$0.02M |
|
-- |
|
-- |
|
$0.02M |
|
$11.73M |
|
-- |
|
$0.17M |
|
$11.90M |
|
$-11.90M |
|
$-11.88M |
|
$-11.88M |
|
125.54M |
|
| Cash Flow Statement Financials | |
$-0.14M |
|
-- |
|
$0.14M |
|
$0.00M |
|
$0.00M |
|
$-0.00M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.00 |
|
-- |
|
-- |
|
-- |
|
-0.23 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.14M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
17.67% |
|
17.70% |
|
-9230.15% |
|
17.70% |
|
$-0.09 |
|
$-0.00 |
|
$-0.00 |
|